HM15136

long-acting glucagon analogue

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Overweight 01/01/2023 - "Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities." 01/01/2023 - "To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D). "
2.	Congenital Hyperinsulinism 10/06/2022 - "A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism."
3.	Weight Loss (Weight Reduction) 01/01/2023 - "Dose-dependent increases in mean HM15136 serum concentration and fasting plasma glucose (FPG) were observed, as were dose-dependent weight reductions of 0.5%/2.3%/2.6% at doses of 0.02/0.04/0.06 mg/kg, respectively. "
4.	Hypoglycemia (Reactive Hypoglycemia) 10/06/2022 - "Further, HM15136 could effectively reverse acute hypoglycemia induced by insulin challenge, and multiple doses of HM15136 could sustain increased blood glucose levels in CHI rats. "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2023 - "To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight/obese patients with co-morbidities, with and without type 2 diabetes (T2D). "